Please login to the form below

Not currently logged in
Email:
Password:

Xoma

This page shows the latest Xoma news and features for those working in and with pharma, biotech and healthcare.

Novartis adds to immuno-oncology pipeline once again

Novartis adds to immuno-oncology pipeline once again

a $500m deal to license transforming growth factor (TGF) beta-targeting antibodies from US firm Xoma earlier this month.

Latest news

  • Novartis signs $500m immuno-oncology deal Novartis signs $500m immuno-oncology deal

    Novartis signs $500m immuno-oncology deal. Gains access to Xoma's TGFb antibody programme. ... According to Xoma, three isoforms of TGFb exist in humans: TGFb1, 2 and 3.

  • Boehringer to manufacture Servier’s gevokizumab

    Boehringer Ingelheim has agreed a deal with Servier and its development partner Xoma to manufacture its inflammatory disease monoclonal antibody candidate gevokizumab. ... While financial terms were not disclosed, Servier and Xoma will retain all

  • Creative partnerships

    Other deals in these diseases were Amgen's option deal with Xencor, Astellas and AVEO, Servier's deal with Xoma and Pfizer's deals with Seattle Genetics and Theraclone Sciences. ... 1, 400. XOMA/Les Laboratoires Servier ##. XOMA052 anti-inflammatory.

  • Xoma, Servier diabetes drug fails trial

    The partners expect to begin clinical studies of Xoma 052 in cardiovascular disease in 2012. ... Xoma and Servier announced their development and commercialisation deal for the drug in January.

  • Scratching the surface

    Amevive was followed by Immunex's Enbrel (etanercept), Abbott's Humira (adalimumab), Johnson &Johnson's Remicade (infliximab) and Genentech and XOMA's Raptiva (efalizumab).

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    14%. $3.7bn. ($4.0bn). Cerecor. 4.0. 0.7. -82%. $0.6m. ($16m). Xoma. 11.7. ... 816 (upfront 18.5). Xoma (US). Novartis (CH). 2 licences: gevokizumab and IP.

  • Deal Watch December 2015 Deal Watch December 2015

    335. Xoma (US). Novo Nordisk. Collaboration, licence. Development and commercialisation of allosteric monoclonal antibodies that up-regulate the insulin receptor.

  • Deal Watch October 2015 Deal Watch October 2015

    Research collaboration, licence. 535. XOMA Corporation/ Novartis. Anti-transforming growth factor-beta (TGFb) antibody programme incl XOMA089 plus other TGFb1 inhibitors (pc).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics